Loading
A phase 3 trial of Giredestrant, Fulvestrant, Abemaciclib, Palbociclib and Ribociclib in HR-positive / HER2-negative breast cancer, run by Hoffmann-La Roche, active and no longer recruiting.
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) is a phase 3 interventional study registered as NCT06065748 by Hoffmann-La Roche, with 1050 participants enrolled, started 2023-12-11 and due to reach its primary completion in 2028-04-20. Interventions recorded: Giredestrant, Fulvestrant, Abemaciclib, Palbociclib, Ribociclib and LHRH Agonist.
Shares Giredestrant, Flatiron Health (Roche), Abemaciclib, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Ribociclib, Abemaciclib and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.